pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 24·1 min read
save

Novo Nordisk seeks court order to halt Lilly GLP-1 ads as Merck announces HIV PrEP partnership

Jul 24, 2026·read at Endpoints ↗DealNeutral

Novo Nordisk asked a New Jersey federal court to temporarily block Eli Lilly's GLP-1 advertisements, claiming the ads are misleading.

Merck disclosed that it has entered into a partnership focused on HIV pre‑exposure prophylaxis (PrEP), though the terms of the deal were not detailed.

The briefing also mentioned additional moves by AbbVie, Genmab, Johnson & Johnson and Mannkind, but no further information was provided.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal”

read at Endpoints ↗
81 words · retrieved Jul 24
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO4LILLY3MANNKIND3ABBVIE2JOHNSON & JOHNSON2Novo Nordisk Inc2ELI LILLY CO
topics
GLP-1 receptor3Monoclonal AntibodyVaccines

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 1d agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech
  • Aug 27Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateBioSpace
  • Jul 21Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityBioSpace